CNS Therapeutics

About CNS Therapeutics

CNS Pharmaceuticals is a clinical-stage biopharmaceutical company developing anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. The company's primary focus is on treating glioblastoma multiforme (GBM), an aggressive and typically incurable form of brain cancer. The business model centers on advancing its pipeline through clinical trials to gain regulatory approval and commercialize its therapies.

The company was incorporated in 2017 and is headquartered in Houston, Texas. Its lead drug candidate, Berubicin, was developed by Dr. Waldemar Priebe at The University of Texas MD Anderson Cancer Center. A key feature of Berubicin is that it appears to be the first anthracycline, a powerful class of chemotherapy drugs, capable of crossing the blood-brain barrier to target tumor cells directly in the brain. This differentiates it from previously studied anthracyclines that are ineffective against brain tumors due to their inability to cross this barrier. Berubicin functions as a topoisomerase II inhibitor, which interferes with DNA replication in rapidly growing cancer cells, leading to their death. The company has received Orphan Drug designation for Berubicin from the FDA. As of early 2025, CNS Pharmaceuticals is conducting a late-stage, global clinical trial to evaluate Berubicin's efficacy in treating recurrent GBM. The company's second drug candidate, TPI 287, is a taxane that has also shown potential to cross the blood-brain barrier and has been tested in trials for various CNS tumors.

The company is led by CEO John Climaco, a seasoned executive with extensive experience in leadership roles at various healthcare companies, including Axial Biotech, a DNA diagnostics company. His background as a corporate attorney and his experience in taking a diagnostics company from inception to commercialization, along with his involvement in several corporate turnarounds, inform his leadership at CNS Pharmaceuticals. The management team also includes professionals with deep expertise in medicine, clinical operations, and finance.